The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Study published

26 Jun 2008 10:00

RNS Number : 5505X
ReGen Therapeutics PLC
26 June 2008
 



Embargoed for 10am 26 June 2008

ReGen Therapeutics Plc

Study showing that ReGen's ColostrininTM protects hippocampal cells against beta-amyloid and oxidative stress is to be presented at the FENS Forum 2008

ReGen Therapeutics Plc ('ReGen' or 'the Company') announces the publication of a new study showing that ReGen's ColostrininTM protects hippocampal cells against beta-amyloid and oxidative stress. The research, which has been performed by ReGen's collaborators at the Open University, Milton Keynes, United Kingdom is to be presented as a poster at the FENS Forum 2008*, Geneva on 16 July 2008.It has previously been shown that Colostrinin™ can prevent beta-amyloid induced impairment of learning in newly hatched chicks [1] and can protect standardised laboratory neurological cells against beta-amyloid induced toxicity and oxidative stress induced damage [2]. However, the research presented at the FENS Forum is the first study to show these effects on isolated hippocampal cells. 

Commenting on the study, Professor Mike Stewart the senior investigator and scientific advisor to ReGen said 

"These findings are very significant as the hippocampus is one of the key brain areas known to be affected in neurodegenerative diseases such as Alzheimer's disease. It is of particular importance to note that Colostrinin™ can directly protect these neurons that have such an important role in cognition and memory".

Percy Lomax, Chairman and Chief Executive of ReGen said

"This research gives us further confidence in promoting Colostrinin™/CogniSure™ as a nutraceutical for healthy brain ageing. Longer term it adds to our belief that our peptide programme may be able to produce a pharmaceutical product with utility in Alzheimer's disease and other similar neurological disease conditions".

A copy of the full abstract is available at:

http://fens2008.neurosciences.asso.fr/pages/posters_sessions.html 

(Poster session 7 - Wednesday, July 16, 09:30-13:00, Section P217 - C: Alzheimer's 4). Froud K., Saffrey M. J., Stewart M. G., Banks D. & Wardhaugh T. 

* The FENS Forum is the premier European Neuroscience meeting of 2008 

1. Boldogh, I, Kruzel, M. L Journal of Alzheimer's Disease 13 (2008) 303-321  2. Banks D, Stewart M. G. Soc Neurosci Abstr proceedings (2006) 674.5.

 

For further information:

Percy Lomax

ReGen Therapeutics Plc

Tel No 020 7153 4920

Roland Cornish/Felicity Geidt

Beaumont Cornish

Tel No 020 7628 3396

David Scott/Nick Bealer

Alexander David

Tel No 020 7448 9800

Adrian Duffield/Jon Davies

College Hill Associates

Tel No 020 7457 2020

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKGGZVKKKGRZM
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.